GIP and GLP-1 in Type 1 Diabetes
GIP and GLP-1 in Type 1 Diabetes
Investigation of Glucose-dependent Insulinotropic Polypeptide (GIP) effects at hyper and
 hypoglycemia in type 1 diabetes.
Inclusion Criteria:

 • Diagnosed with type 1 diabetes (WHO criteria)

 Exclusion Criteria:

 -  HbA1c > 9 %

 -  Liver disease (ALAT/ASAT > 2 x upper normal limit)

 -  Diabetic nephropathy (s-creatinine > 130 µM or albuminuria)

 -  Proliferative diabetic retinopathy (anamnestic)

 -  Severe arteriosclerosis or heart failure (NYHA group III or IV)

 -  Anemia

 -  treatment with medication not applicable to pause for 12 hours

 -  C-peptide increase after 50 g iv arginine